Concurrent chemoradiotherapy versus radiotherapy alone for "biopsy-only" glioblastoma multiforme.

Autor: Kole AJ; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut., Park HS; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut., Yeboa DN; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut., Rutter CE; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut., Corso CD; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut., Aneja S; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut., Lester-Coll NH; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut., Mancini BR; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut., Knisely JP; Department of Radiation Medicine, Northwell Health System and Hofstra Northwell School of Medicine, Lake Success, New York., Yu JB; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut.
Jazyk: angličtina
Zdroj: Cancer [Cancer] 2016 Aug 01; Vol. 122 (15), pp. 2364-70. Date of Electronic Publication: 2016 May 12.
DOI: 10.1002/cncr.30063
Abstrakt: Background: Combined temozolomide and radiotherapy (RT) is the standard postoperative therapy for glioblastoma multiforme (GBM). However, the clearest benefit of concurrent chemoradiotherapy (CRT) observed in clinical trials has been among patients who undergo surgical resection. Whether the improved survival with CRT extends to patients who undergo "biopsy only" is less certain. The authors compared overall survival (OS) in a national cohort of patients with GBM who underwent biopsy and received either RT alone or CRT during the temozolomide era.
Methods: The US National Cancer Data Base was used to identify patients with histologically confirmed, biopsy-only GBM who received either RT alone or CRT from 2006 through 2011. Demographic and clinicopathologic predictors of treatment were analyzed using the chi-square test, the t test, and multivariable logistic regression. OS was evaluated using the log-rank test, multivariable Cox proportional hazard regression, and propensity score-matched analysis.
Results: In total, 1479 patients with biopsy-only GBM were included, among whom 154 (10.4%) received RT alone and 1325 (89.6%) received CRT. The median age at diagnosis was 61 years. CRT was associated with a significant OS benefit compared with RT alone (median, 9.2 vs 5.6 months; hazard ratio [HR], 0.64; 95% confidence interval [CI], 0.54-0.76; P < .001). CRT was independently associated with improved OS compared with RT alone on multivariable analysis (HR, 0.71; 95% CI, 0.60-0.85; P < .001). A significant OS benefit for CRT persisted in a propensity score-matched analysis (HR, 0.72; 95% CI, 0.56-0.93; P = .009).
Conclusions: The current data suggest that CRT significantly improves OS in patients with GBM who undergo biopsy only compared with RT alone and should remain the standard of care for patients who can tolerate therapy. Cancer 2016;122:2364-2370. © 2016 American Cancer Society.
(© 2016 American Cancer Society.)
Databáze: MEDLINE
Externí odkaz: